Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinued Administration of Growth Hormone in Children with IUGR
NCT01734447Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2000
- Primary completion
- Apr 2003
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of somatropin in Small for gestational age (SGA) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Glucose tolerance as assessed by hyperglycaemia induced by oral ingestion. Started Apr 2000; status: completed.
02
Drugs
somatropin
03
Conditions
Small for gestational age (SGA)
Beyond the preview
Go deeper on NCT01734447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734447.